Clark Madison, Suur Bianca E, Soták Matúš, Börgeson Emma
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Curr Opin Endocr Metab Res. 2024 Sep;36:100539. doi: 10.1016/j.coemr.2024.100539.
Adipose tissue inflammation drives systemic pathophysiology, for instance, obesity-related cardiometabolic disease. Specialized pro-resolving lipid mediators are a superfamily of endogenously produced lipids that promote the resolution of inflammation, an actively regulated process. New evidence suggests that such lipids (e.g. lipoxins) could resolve adipose tissue inflammation and, thus, subvert obesity-related diseases. A key feature of pro-resolving lipids is their ability to promote an M2-like macrophage phenotype and enhance efferocytosis while avoiding adverse side-effects typically associated with anti-inflammatory drugs, such as increased sensitivity to infections. This brief review discusses the therapeutic potential of pro-resolving lipid mediators in mitigating systemic disease fueled by adipose tissue inflammation in both experimental and human disease models.
脂肪组织炎症驱动全身病理生理过程，例如肥胖相关的心脏代谢疾病。特殊的促炎症消退脂质介质是内源性产生的脂质超家族，可促进炎症的消退，这是一个积极调控的过程。新证据表明，此类脂质（如脂氧素）可消退脂肪组织炎症，从而颠覆肥胖相关疾病。促炎症消退脂质的一个关键特性是它们能够促进M2样巨噬细胞表型并增强噬菌作用，同时避免通常与抗炎药物相关的不良副作用，如对感染的敏感性增加。本简要综述讨论了促炎症消退脂质介质在减轻实验模型和人类疾病模型中由脂肪组织炎症引发的全身性疾病方面的治疗潜力。
